Clinical Trials Logo

Liposarcoma, Myxoid clinical trials

View clinical trials related to Liposarcoma, Myxoid.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05492682 Recruiting - Colorectal Cancer Clinical Trials

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Start date: February 2, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

NCT ID: NCT05120271 Recruiting - Clinical trials for Hepatocellular Carcinoma

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

DUET-1
Start date: May 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

NCT ID: NCT04794127 Recruiting - Clinical trials for Liposarcoma, Dedifferentiated

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

TRABEPIO
Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 study conducted in two sequential stages: The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who achieved a stable disease after a minimum of 4 cycles of T alone. If a minimum required activity will be demonstrated from the first stage, the second stage of the study will be conducted;otherwise, the study will be stopped. The second stage is an Italian open-label, multicenter, randomized, double arm, phase II trial, aimed at evaluating the combination of T and P in myxoid liposarcoma and G1 or G2 dedifferentiated liposarcomas compared to the standard treatment with T alone. Patients will be randomized with a 1:1 ratio to treatments arms as specified below: - Control arm (A): T alone - Experimental arm (B): T in combination with P

NCT ID: NCT04699292 Recruiting - Myxoid Liposarcoma Clinical Trials

International Prospective Registry on Local Treatment Approaches in MLS

Start date: January 18, 2021
Phase:
Study type: Observational [Patient Registry]

To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)

NCT ID: NCT04044768 Recruiting - Synovial Sarcoma Clinical Trials

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Start date: August 13, 2019
Phase: Phase 2
Study type: Interventional

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

NCT ID: NCT02275286 Recruiting - Leiomyosarcoma Clinical Trials

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

TRASTS
Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma. Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Cohort C: Patients with retroperitoneal and resectable soft tissue sarcoma (liposarcoma and leiomyosarcoma). Cohort D (Phase II only): Patients with well differentiated liposarcoma and G2 dedifferentiated liposarcoma (with less than 30% dedifferentiated component). Phase I: escalating dose of 1.3 or 1.5 mg/m2. Phase I for cohort C: de-escalating dose of 1.5 or 1.3mg/m2 Radiotherapy for cohort A: 30Gy in 10 fractions (3Gy/fraction). Radiotherapy for cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Radiotherapy for cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Radiotherapy for cohort D: 45Gy in 25 fractions (1.8Gy/fraction). A translational substudy is developed to analyse different biomarkers predictive value. Cohorts A and B are closed to recruitment in 2023.